Formulation and evaluation of transdermal patches of selegiline

Selegiline is an antiparkinsonian drug. It is a MAO-B enzyme inhibitor. It undergoes hepatic first pass metabolism and it result in 10% bioavailability on oral administration. So it was designed to formulate transdermal patches of Selegiline HCl for enhancing the bioavailability and patient compliance. Different formulation were prepared by different grades and varying concentration of polymer by solvent casting method. PG was used as permeation enhancer. The films were subjected to evaluation parameters like weight variation, thickness, moisture content, tensile strength, folding endurance, drug content and in-vitro drug release.